Ginkgo Bioworks downgraded by BTIG Research
$DNA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BTIG Research downgraded Ginkgo Bioworks from Neutral to Sell
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2024 | Neutral → Sell | BTIG Research | |
| 5/10/2024 | Mkt Perform → Underperform | William Blair | |
| 11/14/2023 | $3.50 → $2.50 | Outperform → Mkt Perform | Raymond James |
| 11/9/2023 | Buy → Neutral | BTIG Research | |
| 6/2/2023 | $3.00 → $1.25 | Neutral → Sell | Goldman |
| 5/11/2023 | Outperform → Mkt Perform | William Blair | |
| 11/29/2022 | $6.00 | Buy | Berenberg |
| 10/4/2022 | $5.00 | Equal-Weight | Morgan Stanley |
BOSTON, March 2, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA) today announced the official launch of Ginkgo Cloud Lab. This new interface allows researchers to transition their benchwork to Ginkgo's autonomous lab infrastructure directly through a web browser. Ginkgo Cloud Lab runs on the company's proprietary Reconfigurable Automation Carts (RACs). These modular units combine high-precision robotic arms, maglev sample transport tracks, and industrial-grade software to create an endlessly flexible laboratory environment.The Cloud Lab provides remote access to a fleet of over
Ginkgo provides an update on its fourth quarter financial resultsBOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. Fourth Quarter 2025 Financial ResultsFourth quarter 2025 Total revenue of $33 million compared to $44 million in the comparable prior year pe
Presentation and Q&A session scheduled for post-market on Thursday, February 26, 2026BOSTON, Feb. 19, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.To ask a
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
S-8 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
10-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
BTIG Research downgraded Ginkgo Bioworks from Neutral to Sell
William Blair downgraded Ginkgo Bioworks from Mkt Perform to Underperform
Raymond James downgraded Ginkgo Bioworks from Outperform to Mkt Perform and set a new price target of $2.50 from $3.50 previously
Carrithers brings to Merlin a unique blend of technical expertise, capital markets experience, and operational rigor, backed by a proven record in scaling innovative automation and aerospace companies Merlin Labs, Inc., a leading developer of assured, autonomous flight technology for defense customers, today appointed Ryan Carrithers as its new Chief Financial Officer. Carrithers joins Merlin at a pivotal moment as the company prepares to go public in a Business Combination with Inflection Point Acquisition Corp. IV (NASDAQ:BACQ). In this role, he will oversee all of Merlin's financial operations and strategy, investor relations, M&A or strategic partnerships that support its autonomy road
DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man
Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to support internal programs. BOSTON, Aug. 12, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced the appointment of Brian O'Sullivan as Head of Commercial for Ginkgo Automation. Brian joins Ginkgo Automation from HighRes Biosolutions, where he led their commercial efforts. In his new role, Brian wi
Ginkgo provides an update on its fourth quarter financial resultsBOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. Fourth Quarter 2025 Financial ResultsFourth quarter 2025 Total revenue of $33 million compared to $44 million in the comparable prior year pe
Presentation and Q&A session scheduled for post-market on Thursday, February 26, 2026BOSTON, Feb. 19, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.To ask a
Ginkgo provides an update on its third quarter financial results BOSTON, Nov. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced its results for the third quarter ended September 30, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. Third Quarter 2025 Financial Results Third quarter 2025 Total revenue of $39 million compared to $89 million in the comparable prior year period, a decrea
SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)